PORT WASHINGTON, N.Y., Jan. 29, 2018 /PRNewswire/ -- Pall Corporation, a global leader in filtration, separation and purification,has a newly named business unit within the Pall Life Sciences division. The Pall Biotech business unit has been named to reflect an important strategic direction for the company. The update will not impact current or prospective company operations.
Critical partnerships in the industry and alignment with regulatory agencies will play a key role in improving both the integrated and stand-alone elements of the Pall Biotech total bioprocessing solutions portfolio.
"Pall Biotech does not make drugswe enable drug manufacturers with rapid transition from pre-clinical to commercial manufacturing," explained Martin Smith, Chief Technology Officer of Pall Corporation. "In 2018, our Pall Life Sciences division boasts the most complete solutions from drug discovery through delivery with Pall Laboratory for research and discovery, Pall Biotech enabling next-generation manufacturing processes, and Pall Medical for patient delivery."
The Pall Biotech portfolio of standard configurable single-use, stainless steel and hybrid technologies for fed-batch and continuous processes across upstream, downstream and formulation and filling applications enables customers to accelerate time to market by selecting cost effective, robust and reliable integrated solutions. Each customer is fully supported by Pall Biotech experts at both a local and global level.
To learn more about the new Pall Biotech, please visit www.pall.com/biotech. Or to start a conversation with our team and learn how we can support your process success, email: firstname.lastname@example.org.
About Pall CorporationPall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit www.pall.com.
Or follow us on social media: Google+ - YouTube - LinkedIn - Twitter - Facebook
Corporate Media ContactPall Corporation Mariann KourafasDirector of Communications+1-508-871-5469
Media ContactWhite Matter CommunicationsBeth Willers email@example.com+1-415-905-0324
View original content:http://www.prnewswire.com/news-releases/newly-named-pall-biotech-business-unit-focuses-on-flexible-scalable-end-to-end-drug-manufacturing-models-for-all-development-processes-300589329.html
SOURCE Pall Corporation
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All